News | July 29, 2010

Tricagrelor Recommended for Approval by FDA Committee

July 29, 2010 – A new, highly anticipated antiplatelet drug was recommended yesterday for final approval by the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee. The drug may challenge the current standard therapy of clopidogrel.

The committee voted to recommend that the FDA approve ticagrelor (Brilinta) for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). The panel reviewed data from the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study, an outcomes trial of more than 18,000 patients whose data showed ticagrelor was superior to clopidogrel (Plavix) in the long-term reduction of cardiovascular events. The FDA is expected to make an approval decision in September 2010.

The advisory committee voted 7-1 in favor of ticagrelor being approved for reduction of thrombotic events in patients with non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) acute coronary syndromes (ACS) intended to be managed by percutaneous coronary intervention (PCI). The committee also voted 7-1 to recommend ticagrelor be approved for reduction of thrombotic events in patients with NSTEMI and STEMI intended to be managed medically.

“We are pleased with the advisory committee’s recommendation to support the approval of ticagrelor. We look forward to continued discussions with the FDA as it evaluates the panel’s recommendation and completes its review of the NDA,” said Howard Hutchinson, M.D., chief medical officer, AstraZeneca.

AstraZeneca filed the regulatory submission for ticagrelor in the second half of 2009. The proposed trade name for ticagrelor in the United States is Brilinta, pending approval from the FDA. Ticagrelor is also currently under regulatory review in nine territories around the world, including the European Union, Canada and Brazil.

The FDA frequently convenes advisory committee meetings to obtain independent expert guidance and recommendations on clinical matters. While the FDA is not required to follow this guidance, the agency takes the advice into consideration when rendering its final decisions on pending applications and other public health matters.

The PLATO Study

PLATO was a large (18,624 patients in 43 countries) head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed to establish whether ticagrelor could achieve clinically meaningful CV and safety end points in ACS patients, above and beyond those afforded by clopidogrel. PLATO was designed to reflect current clinical management of ACS patients and included and represented all types of ACS patients (STEMI, NSTEMI and UA) whether they underwent invasive procedures or were medically managed.

As presented to the FDA advisory committee, ticagrelor demonstrated a reduction of CV events (CV death, MI, stroke) over clopidogrel (Plavix/Iscover) (9.8 vs. 11.7 percent at 12 months; 16 percent RRR; 95 poercent CI, 0.77 to 0.92; p

Pharmacology
Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor is the first reversibly binding oral ADP receptor antagonist.

For more information: www.astrazeneca-us.com

Related Content

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Overlay Init